## M Neil Reaume

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9988175/publications.pdf Version: 2024-02-01

45	1 714	623188 <b>14</b>	329751 <b>37</b>
papers	1,714 citations	h-index	g-index
<b>F</b> ·· <b>F</b> ·· <b>F</b>			8
45	45	45	2595
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	13.9	982
2	Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of Clinical Oncology, 2019, 37, 1159-1168.	0.8	112
3	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open, 2021, 4, e2021869.	2.8	104
4	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG) Tj ETQqO 0 (	)ng£sT∤Ov	erkack 10 Tf :
5	A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 457-465.	1.1	41
6	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 2021, 79, 334-338.	0.9	39
7	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. Clinical Lung Cancer, 2014, 15, 52-57.	1.1	32
8	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, 2017, 11, 112.	0.3	32
9	Canadian guideline on genetic screening for hereditary renal cell cancers. Canadian Urological Association Journal, 2013, 7, 319.	0.3	30
10	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq0 0 0	) rgBT /Ov 0.8	erlock 10 Tf 5 29

29

11	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) Journal of Clinical Oncology, 2022, 40, LBA5004-LBA5004.	0.8	29
12	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	0.9	28
13	Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncology, 2020, 6, 1751.	3.4	20
14	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Canadian Urological Association Journal, 2015, 9, 164.	0.3	18
15	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Canadian Urological Association Journal. 2018. 12. 173-80.	0.3	16
16	Structured assessment and followup for patients with hereditary kidney tumour syndromes. Canadian Urological Association Journal, 2016, 10, 214.	0.3	12
17	A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOC) Tj ETQq1 1 C	). <b>788</b> 314	rg <b>B</b> Z /Over
10	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC)	0.3	11

18 consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97. 0.311

837-846.

M NEIL REAUME

#	Article	IF	CITATIONS
19	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.3	10
20	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	0.5	10
21	Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521 Journal of Clinical Oncology, 2020, 38, 333-333.	0.8	10
22	Acute Cardiogenic Shock Induced by Infusional 5-Fluorouracil. Case Reports in Oncological Medicine, 2014, 2014, 1-3.	0.2	9
23	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) Journal of Clinical Oncology, 2020, 38, 642-642.	0.8	9
24	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer, 2021, 19, 521-530.	0.9	8
25	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Canadian Urological Association Journal, 2017, 11, 310-320.	0.3	6
26	The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. Medical Oncology, 2019, 36, 18.	1.2	6
27	Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993) Journal of Clinical Oncology, 2018, 36, 4505-4505.	0.8	6
28	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2019, 37, 4516-4516.	0.8	6
29	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP) Tj ETQq1 LBA2-LBA2.	1 0,7843 0.8	14 rgBT /Ove
30	Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. Canadian Urological Association Journal, 2014, 8, 832.	0.3	5
31	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2017, 35, 468-468.	0.8	4
32	A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197 Journal of Clinical Oncology, 2015, 33, 8046-8046.	0.8	2
33	Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT) Journal of Clinical Oncology, 2018, 36, 193-193.	0.8	2
34	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis Journal of Clinical Oncology, 2020, 38, 5068-5068.	0.8	2
35	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 5071-5071.	0.8	2
36	CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570) Journal of Clinical Oncology, 2022, 40, TPS4619-TPS4619.	0.8	2

M NEIL REAUME

#	Article	IF	CITATION
37	Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2020, 38, 620-620.	0.8	1
38	A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993) Journal of Clinical Oncology, 2015, 33, TPS4573-TPS4573.	0.8	0
39	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2017, 35, e16078-e16078.	0.8	0
40	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
41	Application of Canadian hereditary renal cell carcinoma risk criteria to a population database Journal of Clinical Oncology, 2018, 36, 621-621.	0.8	0
42	The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity Journal of Clinical Oncology, 2018, 36, e17005-e17005.	0.8	0
43	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer Journal of Clinical Oncology, 2019, 37, e16501-e16501.	0.8	0
44	The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials Journal of Clinical Oncology, 2020, 38, e14099-e14099.	0.8	0
45	Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2020, 38, 633-633.	0.8	0